Coming off a strong first quarter, in which sales of cabozantinib solidly bested Street expectations, Exelixis Inc. made another move to expand its early stage pipeline via a collaboration with multispecific antibody firm Invenra Inc. The two will work together using Invenra's B-Body technology platform to identify candidates for treating cancer.